Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C92H175N2O17P.C6H15N |
| Molecular Weight | 1713.5409 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC.CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)NCCO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC
InChI
InChIKey=QOFRNSMLZCPQKL-KTIIIUPTSA-N
InChI=1S/C92H175N2O17P.C6H15N/c1-7-13-19-25-31-37-40-46-52-58-64-70-85(98)106-79(67-61-55-49-43-34-28-22-16-10-4)75-83(96)93-73-74-105-92-89(94-84(97)76-80(68-62-56-50-44-35-29-23-17-11-5)107-86(99)71-65-59-53-47-41-38-32-26-20-14-8-2)91(90(82(78-95)109-92)111-112(102,103)104)110-88(101)77-81(69-63-57-51-45-36-30-24-18-12-6)108-87(100)72-66-60-54-48-42-39-33-27-21-15-9-3;1-4-7(5-2)6-3/h79-82,89-92,95H,7-78H2,1-6H3,(H,93,96)(H,94,97)(H2,102,103,104);4-6H2,1-3H3/t79-,80-,81-,82-,89-,90-,91-,92-;/m1./s1
| Molecular Formula | C92H175N2O17P |
| Molecular Weight | 1612.3509 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C6H15N |
| Molecular Weight | 101.19 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:39:13 GMT 2025
by
admin
on
Mon Mar 31 23:39:13 GMT 2025
|
| Record UNII |
FQR7P879JZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
FQR7P879JZ
Created by
admin on Mon Mar 31 23:39:13 GMT 2025 , Edited by admin on Mon Mar 31 23:39:13 GMT 2025
|
PRIMARY | |||
|
216014-46-9
Created by
admin on Mon Mar 31 23:39:13 GMT 2025 , Edited by admin on Mon Mar 31 23:39:13 GMT 2025
|
PRIMARY | |||
|
9964020
Created by
admin on Mon Mar 31 23:39:13 GMT 2025 , Edited by admin on Mon Mar 31 23:39:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Hepatitis B vaccine; Mechanism of Action: Immunostimulant; Highest Development Phase: No development reported for Hepatitis B; Most Recent Events: 03 Apr 2009 No development reported - Preclinical for Hepatitis B in Germany (Parenteral), 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics, 25 Jul 2003 Preclinical trials in Hepatitis B treatment in Germany (unspecified route)
|
||
|
ACTIVE MOIETY |
MPL (Corixa) adjuvant is a chemically modified derivative of lipopolysaccharide that displays greatly reduced toxicity while maintaining most of the immuno-stimulatory activity of lipopolysaccharide. One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies.
|
||
|
ACTIVE MOIETY |
Clinical Trial Coverage: No. of Trials involving Product
|
